ScienceDaily (Jan. 30, 2012) — The    vaccines of the future against infections, influenza and cancer    can be administered using an electrical pulse and a    specially-produced DNA code from the University of Oslo. The    DNA code programs the body's own cells to produce a super-fast    missile defence against the disease.  
    Researchers at the University of Oslo,Norway have developed a    new type of DNA vaccine that can be used effectively against    viruses and cancer. Studies reveal that the new vaccine    triggers a powerful immune response. The vaccine has been    tested on mice. Now the researchers hope the vaccine can be    tested clinically.  
    This vaccine has an additional advantage. At the moment,    vaccines require the inclusion of immuno-activating substances.    These substances are called adjuvants and are    generally composed of oil-based mixtures or aluminium salts.    Adjuvants initiate local and often painful inflammation at the    injection site. This inflammation fools the immune system into    reacting to the vaccine.  
    Without additives  
    The new vaccine from the University of Oslo does not need the    addition of adjuvants. Instead, a completely new technology is    used that applies an electrical current to the injection site    immediately after injection. This electrical pulse results in a    molecular reaction.  
    "The advantage of this type of reaction is two-fold. Firstly,    one injection is enough and, secondly, the immune system reacts    very quickly and effectively," points out Professor Bjarne    Bogen at the Centre for Immune Regulation at the    University of Oslo. Bogen has developed this new vaccine    technology together with Professor Inger Sandlie,    post-doctorate Agnete B. Fredriksen and a number of    other co-workers.  
    The possibilities with this new vaccine from UiO are numerous.    This new vaccine technology means it will be possible to    produce vaccines quickly enough to protect against new    pandemics, influenza epidemics, or hostile biological threats.  
    No need to cultivate viruses in eggs  
    It is time-consuming to make traditional vaccines. Today, in    order to make influenza vaccines, viruses have to be cultivated    in eggs. It can take almost a year before the vaccine is ready    to use.  
    "The first problem: the world does not have enough eggs to    produce influenza vaccine quickly enough for everybody. The    second problem: certain forms of the deadly bird flu kill the    eggs. Fatality can be as high as 50%. If a new influenza virus    kills the eggs, it will not be possible to make a vaccine,"    explains Bjarne Bogen to the research-magazine Apollon.  
    His research team is now studying whether it is possible to use    this new vaccine technology to develop a rapid and effective    vaccine against influenza.  
    DNA is the solution  
    The new vaccine is composed of DNA strands. To make a new    vaccine, constructing just a section of DNA is enough. Bacteria    are good DNA factories. By adding a special substance, the    bacteria double the number of DNA strands every 20 mins. This    means an 8-fold increase in an hour. Over 24 hours, the    bacteria will have produced vast quantities of DNA strands. The    DNA strands then need to be cleaned free of the bacteria. This    copying method is used by everybody working with DNA.  
    Programs the cells in the body  
    The researchers have called the active component in this new    vaccine technology Vaccibody.  
    When DNA is injected together with an electric pulse, DNA is    taken up in the skin cells. The cells then read-off the DNA and    produce some very special proteins. It is these proteins that    are called Vaccibody molecules and to which the immune system    reacts so strongly.  
    This means: the researchers have found the DNA code that    programs skin cells in the body to make Vaccibody molecules.  
    Made up of three parts  
    The Vaccibody molecules are composed of three components. Each    of them has an important role in the immune system. The first    component is the target guidance system which, like a pair of    gripping pliers, binds to dendrite cells, a type of immune cell    discovered by Ralph Steinman, who last year was    awarded the Nobel Prize in Medicine.  
    The second component of the Vaccibody molecules ensures that    two identical chains are held together. Tests reveal that this    special architecture is highly important if the vaccine is to    work.  
    The third component of the Vaccibody molecule is a small piece    of a virus, a bacteria or cancer cell. This small piece is    called an antigen.  
    "The Vaccibody molecules are made so that we can insert all    types of antigens. The only condition is that the antigen has a    protein structure. We have inserted bits from numerous    different viruses and bacteria. All have worked. We have also    been able to successfully insert an antigen made up of 523    amino acids. This is an enormous molecule."  
    The Vaccibody molecules attach to the dendrite cells and are    taken to the lymph nodes which are the headquarters of the    immune system. There, the dendrite cells "display" the antigen    to the most important cells in the immune system, the B cells    and T cells.  
    Not only does this result in large-scale production of B cells,    but the immune system is also stimulated to produce aggressive    T cells.  
    "Both of these parts of the immune defence are as a rule    important in our protection against viruses and bacteria, and    for eliminating cancer cells. This means that Vaccibody offers    double protection."  
    Target guiding gripping pliers  
    In some types of Vaccibody molecules, the gripping pliers that    attach to the dendrite cells are a chemokine. Chemokines are    small hormone-like substances that guide the passage of cells    through the body.  
    "We have achieved very good results from our studies with    Vaccibody molecules guided using chemokines. The chemokines can    be thought of as lighthouses along the coast. They enable the    immune cells to navigate correctly and have a special effect on    the production of T cells, an attribute that is very important    in fighting viruses and cancer," underscores Bogen.  
    Successful test  
    The Vaccibody vaccine has so far been tested on mice with    cancer and influenza. Eighty percent of the vaccinated mice    became resistant to cancer. 100% of those vaccinated were    protected against flu. The protection was effective very    quickly. Bjarne Bogen hopes that a number of major companies    can test the vaccine clinically on people.  
    Post-doctorate Ranveig Braathen is now developing the    second generation Vaccibody where, with the help of molecular    cloning, she is testing new variants of the gripping pliers to    optimise its efficiency.  
    Post-doctorate Even Fossum is looking at how Vaccibody    can be used to improve the vaccine against tuberculosis. In    spite of today's vaccine against tuberculosis, 1.5 million    people die every year of this disease. The new vaccine will    ensure a much improved immune response against this feared    disease.  
    Post-doctorate Inger Øynebråten is applying Vaccibody    technology in the hope of making a vaccine against HIV. PhD    students Gunnveig Grødeland, Marta Baranowska    and Ane Marie Andersson are using Vaccibody to develop    new vaccines against influenza.  
    Post-doctorate Agnete Brunsvik and PhD student    Heidi Spång are using the technology to develop a    cancer vaccine for patients with bone marrow cancer and    melanoma.  
    Recommend this story on Facebook,    Twitter,
    and Google +1:  
    Other bookmarking and sharing tools:  
    St
ory Source:  
      The above story is reprinted from materials provided by University of      Oslo, via AlphaGalileo.    
      Note: Materials may be edited for content and length. For      further information, please contact the source cited      above.    
      Note: If no author is given, the source is cited      instead.    
    Disclaimer: This article is not intended    to provide medical advice, diagnosis or treatment. Views    expressed here do not necessarily reflect those of ScienceDaily    or its staff.  
Go here to see the original:
Targeted DNA vaccine using an electric pulse